Company: DVAX
Filing Date: 2025-05-19
Form Type: DFAN14A
Source: 0001193125-25-122435
Chunk: 2

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-19
Form: DFAN14A
Chunk 2
---
 Under no circumstances is this Presentation to be used or considered as an offer to sell or a solicitation of an offer to buy any security. All registered or unregistered service marks, trademarks, and trade names referred to in this Presentation are the property of their respective owners, and Deep use herein does not imply an affiliation with, or endorsement by, the owners of such service marks, trademarks and trade names. Deep Track strongly advises all stockholders of the Company to read the definitive proxy statement, any amendments or supplements to such proxy statement and other proxy materials filed by Deep Track with the SEC as they become available because they will contain important information. Such proxy will be available at no charge on the SEC's website at www.sec.gov. The definitive proxy statement and other relevant documents, are also available on www.RefocusDVAX.com and the SEC website, free of charge, or by directing a request to the (as defined below) proxy solicitor, Innisfree, 501 Madison Avenue, 20th Floor, New York, New York, 10022 (stockholders can call toll-free: +1 (877) 687-1865). The Participants (the in the solicitation are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel. 2

Key Points adjuvant, CpG 1018, provides a distinctive competitive edge that will lower development risk and ensure pipeline success. CpG 1018 does not improve the chances of successful development and commercialization.

Overview of Adjuvants and Vaccines An adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better. 1 Dynavax was founded in 1996 on the basis of using proprietary immunostimulatory sequences (ISS) of DNA as adjuvants, one of which is CpG 1018. Each different adjuvant stimulates different immune responses and must be carefully studied. Different combinations of adjuvants and other vaccine components stimulate different immune responses and must be carefully studied dicate that owning CpG 1018 does not uniquely position Dynavax for success in creating new vaccines. 2 Adjuvants used in U.S. vaccines Adjuvant Composition Vaccines Aluminum One or more of the following: amorphous aluminum hydroxyphosphate sulfate Anthrax